Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy
Authors
Keywords
-
Journal
JACC-Cardiovascular Interventions
Volume 14, Issue 7, Pages 739-750
Publisher
Elsevier BV
Online
2021-03-19
DOI
10.1016/j.jcin.2021.01.024
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel
- (2020) Dominick J. Angiolillo et al. JACC-Cardiovascular Interventions
- The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
- (2020) Jean-Philippe Collet et al. EUROPEAN HEART JOURNAL
- Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention
- (2020) Naveen L. Pereira et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clopidogrel Pharmacogenetics
- (2019) Naveen L. Pereira et al. Circulation-Cardiovascular Interventions
- Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
- (2019) Dirk Sibbing et al. JACC-Cardiovascular Interventions
- A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
- (2019) Daniel M.F. Claassens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
- (2019) Stefanie Schüpke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
- (2018) Larisa H. Cavallari et al. JACC-Cardiovascular Interventions
- Clinical Practice Guidelines
- (2017) M. Hassan Murad MAYO CLINIC PROCEEDINGS
- Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI)
- (2017) Shuxia Chen et al. MEDICAL SCIENCE MONITOR
- High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial
- (2016) Yunmei Zhang et al. ACTA CARDIOLOGICA
- Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands
- (2016) B. A. L. M. Deiman et al. Netherlands Heart Journal
- Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes
- (2016) Peng Dong et al. MEDICAL SCIENCE MONITOR
- Genotype-based clinical trials in cardiovascular disease
- (2015) Naveen L. Pereira et al. Nature Reviews Cardiology
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
- (2013) S A Scott et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- TheCYP2C19*17 variant is not independently associated with clopidogrel response
- (2013) J. P. Lewis et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding
- (2012) Thomas M. Polasek et al. THROMBOSIS AND HAEMOSTASIS
- Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
- (2010) Dirk Sibbing et al. CIRCULATION
- ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
- (2010) David R. Holmes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
- (2010) Lars Wallentin et al. LANCET
- Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel
- (2009) Jessica L. Mega et al. CIRCULATION
- The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
- (2009) C. FRÉRE et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Cardiovascular pharmacogenomics and individualized drug therapy
- (2009) Naveen L. Pereira et al. Nature Reviews Cardiology
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
- (2009) Lars Wallentin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytochrome P-450 Polymorphisms and Response to Clopidogrel
- (2008) Jessica L. Mega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
- (2008) Tabassome Simon et al. NEW ENGLAND JOURNAL OF MEDICINE
- CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation
- (2008) Tobias Geisler et al. PHARMACOGENOMICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now